The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Comprehensive molecular portraits of human breast tumours
Open accessAbstract
We analysed primary breast cancers by genomic DNA copy number arrays, DNA methylation, exome sequencing, messenger RNA arrays, microRNA sequencing and reverse-phase protein arrays. Our ability to integrate information across platforms provided key insights into previously defined gene expression subtypes and demonstrated the existence of four main breast cancer classes when combining data from five platforms, each of which shows significant molecular heterogeneity. Somatic mutations in only three genes (TP53, PIK3CA and GATA3) occurred at >10% incidence across all breast cancers; however, there were numerous subtype-associated and novel gene mutations including the enrichment of specific mutations in GATA3, PIK3CA and MAP3K1 with the luminal A subtype. We identified two novel protein-expression-defined subgroups, possibly produced by stromal/microenvironmental elements, and integrated analyses identified specific signalling pathways dominant in each molecular subtype including a HER2/phosphorylated HER2/EGFR/phosphorylated EGFR signature within the HER2-enriched expression subtype. Comparison of basal-like breast tumours with high-grade serous ovarian tumours showed many molecular commonalities, indicating a related aetiology and similar therapeutic opportunities. The biological finding of the four main breast cancer subtypes caused by different subsets of genetic and epigenetic abnormalities raises the hypothesis that much of the clinically observable plasticity and heterogeneity occurs within, and not across, these major biological subtypes of breast cancer. The Cancer Genome Atlas Network describe their multifaceted analyses of primary breast cancers, shedding light on breast cancer heterogeneity; although only three genes (TP53, PIK3CA and GATA3) are mutated at a frequency greater than 10% across all breast cancers, numerous subtype-associated and novel mutations were identified. This Article from the Cancer Genome Atlas consortium describes a multifaceted analysis of primary breast cancers in 825 people. Exome sequencing, copy number variation, DNA methylation, messenger RNA arrays, microRNA sequencing and proteomic analyses were performed and integrated to shed light on breast-cancer heterogeneity. Just three genes — TP53, PIK3CA and GATA3 — are mutated at greater than 10% frequency across all breast cancers. Many subtype-associated and novel mutations were identified, as well as two breast-cancer subgroups with specific signalling-pathway signatures. The analyses also suggest that much of the clinically observable plasticity and heterogeneity occurs within, and not across, the major subtypes of breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In breast cancer, hypoxia is more evident in TNBC than in other breast cancer subtypes11,12.”
From Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy (2022) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoxia-inducible factor 1α (HIF-1α) is a master transcription factor that is highly expressed in cancer tissues, including breast cancer, and is particularly enriched in triple-negative breast cancer (TNBC)2.”
From Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“A recent analysis, combining mutation, mRNA expression and protein levels, determined that the PI3K/Akt pathway was elevated in basal-like cancers as compared with luminal or HER2+ (47).”
From Mislocalization of the Cell Polarity Protein Scribble Promotes Mammary Tumorigenesis and Is Associated with Basal Breast Cancer (2014) · cites this paper as [47]
In the citing paper
“data analysis of The Cancer Genome Atlas (TCGA) dataset11 identified that hypoxic gene signature, which includes commonly documented hypoxia-responsive genes26, was inversely correlated with immune effector genes (IFNG, TNF, GZMB, PRF1), IFNγ-responsive genes, as well as genes associated with tumor-infiltrating lymphocytes (TILs) in TNBC (n = 99) (also referred as a basal subtype of breast cancer)”
In the citing paper
“Kaplan–Meier analysis using public breast cancer meta-analysis database11,30 reveals that TNBC patients with higher hypoxia gene signature are associated with worse disease outcomes, including both overall survival (OS) and distant metastasis-free survival (DMFS), compared to those with lower expression of hypoxia gene signature (Fig. 1h).”
In the citing paper
“Analysis of hundreds of triple-negative breast cancers revealed a wide diversity of somatic mutations none of which were found at high frequency [4].”
From The hypoxic tumor microenvironment: A driving force for breast cancer progression (2016) · cites this paper as [4]
In the citing paper
“Given the remarkable overexpression of HIF target genes in triple-negative breast cancer [4, 21], the master regulatory role of HIFs in metastasis (Fig. 5), and their involvement in chemotherapy resistance, HIF inhibitors may represent a targeted therapy for these breast cancers.”
From The hypoxic tumor microenvironment: A driving force for breast cancer progression (2016) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Self-citationA Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J. B., Cronin, M. T., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,321
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R. J., Parker, J. S., Hastie, T. J., Marron, J. S., Nobel, A. B., Deng, S., Johnsen, H., Pesich, R., Geisler, S. B., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,508
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S. C. Y., Voduc, D. K., Vickery, T. L., Davies, S. R., Fauron, C. M. ‐., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,818
Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases
Johnson, G. L., & Lapadat, R. (2002) · Science · doi:10.1126/science.1072682 · Cited by 4,295
Cited by
Sorted by citations
Items 701–800 of 1,085
Liang, Y., Han, H., Liu, L., Duan, Y., Yang, X., Ma, C., Zhu, Y., Han, J., Li, X., & Chen, Y. (2018) · Oncogenesis · doi:10.1038/s41389-018-0107-x · Cited by 203
CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer
Leiserson, M. D. M., Wu, H.-T., Vandin, F., & Raphael, B. J. (2015) · Genome biology · doi:10.1186/s13059-015-0700-7 · Cited by 205
Chen, G., Chakravarti, N., Aardalen, K., Lazar, A. J., Tetzlaff, M. T., Wubbenhorst, B. S., Kim, S.-B., Kopetz, S., Ledoux, A. A., Gopal, Y. N. V., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3003 · Cited by 205
Glucocorticoid Receptor Antagonism as a Novel Therapy for Triple-Negative Breast Cancer
Skor, M. N., Wonder, E. L., Kocherginsky, M., Goyal, A., Hall, B. A., Cai, Y., & Conzen, S. D. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3826 · Cited by 206
Finn, R. S., Liu, Y., Zhu, Z., Martín, M., Rugo, H. S., Dieras, V. C., Im, S., Gelmon, K. A., Harbeck, N., Lu, D. R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0751 · Cited by 204
Takaya, H., Nakai, H., Takamatsu, S., Mandai, M., & Matsumura, N. (2020) · Scientific Reports · doi:10.1038/s41598-020-59671-3 · Cited by 205
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 208
Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer
Kinnel, B., Singh, S. K., Oprea‐Ilies, G., & Singh, R. (2023) · Cancers · doi:10.3390/cancers15041320 · Cited by 209
Therapeutic targeting of tumor suppressor genes
Morris, L. G. T., & Chan, T. A.-T. (2014) · Cancer · doi:10.1002/cncr.29140 · Cited by 209
CD74 and intratumoral immune response in breast cancer
Wang, Z., Milne, K., Webb, J. R., & Watson, P. H. (2016) · Oncotarget · doi:10.18632/oncotarget.8610 · Cited by 202
Hennigs, A., Riedel, F., Gondos, Á., Sinn, H., Schirmacher, P., Marmé, F., Jäger, D., Kauczor, H., Stieber, A., Lindel, K., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2766-3 · Cited by 201
Shu, S., Wu, H., Ge, J. Y., Zeid, R., Harris, I. S., Jovanović, B., Murphy, K. C., Wang, B., Qiu, X., Endress, J. E., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.027 · Cited by 204
Ma, S., Zhao, Y., Lee, W. C., Ong, L.-T., Lee, P. L., Jiang, Z., Oguz, G., Niu, Z., Liu, M., Goh, J. Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31764-9 · Cited by 200
Characterizing DNA methylation alterations from The Cancer Genome Atlas
Weisenberger, D. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69740 · Cited by 200
Wang, P., Bahreini, A., Gyanchandani, R., Lucas, P. C., Hartmaier, R. J., Watters, R. J., Jonnalagadda, A. R., Bittar, H. E. T., Berg, A., Hamilton, R. L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1534 · Cited by 200
Umemura, S., Mimaki, S., Makinoshima, H., Tada, S., Ishii, G., Ohmatsu, H., Niho, S., Yoh, K., Matsumoto, S., Takahashi, A., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000250 · Cited by 200
MAP2K1 and MAP3K1 mutations in langerhans cell histiocytosis
Nelson, D. S., van Halteren, A. G. S., Quispel, W. T., van den Bos, C., Bovée, J. V. M. G., Patel, B., Badalian‐Very, G., Hummelen, P. V., Ducar, M. D., Lin, L., et al. (2015) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22247 · Cited by 199
Genetic and epigenetic aspects of breast cancer progression and therapy.
Byler, S., Goldgar, S., Heerboth, S., Leary, M., Housman, G., Moulton, K. L., & Sarkar, S. (2014) · PubMed · Cited by 199
Araki, K., & Miyoshi, Y. (2017) · Breast Cancer · doi:10.1007/s12282-017-0812-x · Cited by 201
Gandhi, L., Bahleda, R., Tolaney, S. M., Kwak, E. L., Cleary, J. M., Pandya, S. S., Hollebecque, A., Abbas, R., Ananthakrishnan, R., Berkenblit, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.2787 · Cited by 198
Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970
Hall, A. B., Newsome, D., Wang, Y., Boucher, D. M., Eustace, B. K., Gu, Y., Hare, B. J., Johnson, M., Li, H. Y., Milton, S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2158 · Cited by 204
Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer
Al‐Ahmadie, H. A., Iyer, G., Lee, B., Scott, S. N., Mehra, R., Bagrodia, A., Jordan, E., Gao, S. P., Ramirez, R. J., Cha, E. K., et al. (2016) · Nature Genetics · doi:10.1038/ng.3503 · Cited by 200
Kais, Z., Rondinelli, B., Holmes, A. L., O’Leary, C., Kozono, D., D’Andrea, A. D., & Ceccaldi, R. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.031 · Cited by 208
The recurrent architecture of tumour initiation, progression and drug sensitivity
Califano, A., & Alvarez, M. J. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.124 · Cited by 203
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
Schettini, F., Santo, I. D., Rea, C. G., Placido, P. D., Formisano, L., Giuliano, M., Arpino, G., Laurentiis, M. D., Puglisi, F., Placido, S. D., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00608 · Cited by 201
Januškevičienė, I., & Petrikaitė, V. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117009 · Cited by 208
Ngamcherdtrakul, W., Morry, J., Gu, S., Castro, D. J., Goodyear, S. M., Sangvanich, T., Reda, M. M., Lee, R., Mihelic, S. A., Beckman, B. L., et al. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201404629 · Cited by 198
Gasdermin-B Promotes Invasion and Metastasis in Breast Cancer Cells
Hergueta‐Redondo, M., Sarrió, D., Molina-Crespo, Á., Megı́as, D., Mota, A., Rojo‐Sebastián, A., García‐Sanz, P., Morales, S., Abril, S., Cano, A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090099 · Cited by 199
A joint analysis of metabolomics and genetics of breast cancer
Tang, X., Lin, C., Spasojević, I., Iversen, E. S., Chi, J., & Marks, J. R. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0415-9 · Cited by 202
DNMT1: A key drug target in triple-negative breast cancer
Wong, K. K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.05.010 · Cited by 200
PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
Zhu, K., Wu, Y. Q., He, P., Fan, Y. J., Zhong, X., Zheng, H. Y., & Luo, T. L. (2022) · Cells · doi:10.3390/cells11162508 · Cited by 197
Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer
Teo, Z. L., Versaci, S., Dushyanthen, S., Caramia, F., Savas, P., Mintoff, C. P., Zethoven, M., Virassamy, B., Luen, S. J., McArthur, G. A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2210 · Cited by 196
Tumor Microenvironment of Metastasis and Risk of Distant Metastasis of Breast Cancer
Rohan, T. E., Xue, X., Lin, H.-M., D’Alfonso, T. M., Ginter, P. S., Oktay, M. H., Robinson, B. D., Ginsberg, M. S., Gertler, F. B., Glass, A. G., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju136 · Cited by 201
Opposing Functions of BRD4 Isoforms in Breast Cancer
Wu, S.-Y., Lee, C.-F., Lai, H., Yu, C., Lee, J., Zuo, H., Tsai, S. Y., Tsai, M., Ge, K., Wan, Y., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.034 · Cited by 201
Pettitt, S. J., Frankum, J. R., Punta, M., Lise, S., Alexander, J. J., Chen, Y., Yap, T. A., Haider, S. A., Tutt, A. N. J., & Lord, C. J. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1485 · Cited by 200
Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma
Lim, W. K., Ong, C. K., Tan, J. Y., Thike, A. A., Ng, C. C. Y., Rajasegaran, V., Myint, S. S., Nagarajan, S., Nasir, N. D. M., McPherson, J. R., et al. (2014) · Nature Genetics · doi:10.1038/ng.3037 · Cited by 195
Mutational Landscape of the Essential Autophagy Gene BECN1 in Human Cancers
Laddha, S. V., Ganesan, S., Chan, C. S., & White, E. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0614 · Cited by 198
OmicCircos: A Simple-to-Use R Package for the Circular Visualization of Multidimensional Omics Data
Hu, Y., Yan, C., Hsu, C.-H., Chen, Q., Niu, K., Komatsoulis, G. A., & Meerzaman, D. M. (2014) · Cancer Informatics · doi:10.4137/cin.s13495 · Cited by 195
An epigenomic approach to therapy for tamoxifen-resistant breast cancer
Feng, Q. F., Zhang, Z., Shea, M. J., Creighton, C. J., Coarfa, C., Hilsenbeck, S. G., Lanz, R. B., He, B., Wang, L., Fu, X., et al. (2014) · Cell Research · doi:10.1038/cr.2014.71 · Cited by 195
Regulators of genetic risk of breast cancer identified by integrative network analysis
Castro, M. A. A., de Santiago, I., Campbell, T. M., Vaughn, C. M., Hickey, T. E., Ross, E. M., Tilley, W. D., Markowetz, F. M., Ponder, B. A. J., & Meyer, K. B. (2015) · Nature Genetics · doi:10.1038/ng.3458 · Cited by 195
Greene, C. S., Tan, J., Ung, M. H., Moore, J. H., & Cheng, C. (2014) · Journal of Cellular Physiology · doi:10.1002/jcp.24662 · Cited by 201
Will, M., Qin, A. C. R., Toy, W., Yao, Z., Rodrik-Outmezguine, V. S., Schneider, C., Huang, X., Monian, P., Jiang, X., de Stanchina, E., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0611 · Cited by 194
Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures
Kan, Z., Ding, Y., Kim, J.-H., Jung, H. H., Chung, W., Lal, S., Cho, S., Fernandez-Banet, J., Lee, S. K., Kim, S. W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04129-4 · Cited by 200
The molecular origin and taxonomy of mucinous ovarian carcinoma
Cheasley, D. A., Wakefield, M. J., Ryland, G. L., Allan, P. E., Alsop, K., Amarasinghe, K. C., Ananda, S. S., Anglesio, M. S., Au‐Yeung, G., Böhm, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11862-x · Cited by 195
Ma, C. X., Bose, R., Gao, F., Freedman, R. A., Telli, M. L., Kimmick, G., Winer, E., Naughton, M., Goetz, M. P., Russell, C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0900 · Cited by 193
A DNA methylation‐based definition of biologically distinct breast cancer subtypes
Stefánsson, Ó. A., Morán, S., Gómez, A., Sayols, S., Arribas-Jorba, C., Sandoval, J., Hilmarsdóttir, H., Ólafsdóttir, E. J., Tryggvadóttír, L., Jonasson, J. G., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.10.012 · Cited by 193
A basal stem cell signature identifies aggressive prostate cancer phenotypes
Smith, B. A., Sokolov, A., Uzunangelov, V., Baertsch, R., Newton, Y., Graim, K. S., Mathis, C., Cheng, D., Stuart, J. M., & Witte, O. N. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518007112 · Cited by 196
She, Q., Gruvberger-Saal, S. K., Maurer, M. S., Chen, Y., Jumppanen, M., Su, T., Dendy, M., Lau, Y.-K. I., Memeo, L., Horlings, H. M., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2609-2 · Cited by 195
Rugo, H. S., André, F., Yamashita, T., Cerda, H., Toledano, I., Stemmer, S. M., Jurado, J. C., Juric, D., Mayer, I., Ciruelos, E. M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.001 · Cited by 193
Mining cancer methylomes: prospects and challenges
Stirzaker, C., Taberlay, P. C., Statham, A. L., & Clark, S. J. (2013) · Trends in Genetics · doi:10.1016/j.tig.2013.11.004 · Cited by 202
Taxonomy of breast cancer based on normal cell phenotype predicts outcome
Santagata, S., Thakkar, A., Ergonul, A. B., Wang, B., Woo, T. Y. C., Hu, R., Harrell, J. C., McNamara, G. T., Schwede, M., Culhane, A. C., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70941 · Cited by 192
The relevance of EMT in breast cancer metastasis: Correlation or causality?
Bill, R., & Christofori, G. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.05.002 · Cited by 192
The nucleosome remodeling and deacetylase complex in development and disease
Basta, J., & Rauchman, M. (2015) · Translational Research · doi:10.1016/j.trsl.2014.05.003 · Cited by 191
Rhee, S., Seo, S., & Kim, S. (2018) · International Joint Conference on Artificial Intelligence · doi:10.24963/ijcai.2018/490 · Cited by 191
The Metabolic Mechanisms of Breast Cancer Metastasis
Wang, L., Zhang, S., & Wang, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.602416 · Cited by 200
PDXNET Consortium, Woo, X. Y., EurOPDX Consortium, Giordano, J., Srivastava, A., Zhao, Z.-M., Lloyd, M. W., de Bruijn, R., Suh, Y.-S., Patidar, R., et al. (2021) · Nature Genetics · doi:10.1038/s41588-020-00750-6 · Cited by 190
Mihály, Z., Kormos, M., Lánczky, A., Dank, M., Budczies, J., Szász, M. A., & Győrffy, B. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2622-y · Cited by 190
Brooks, D. L. P., Schwab, L. P., Krutilina, R. I., Parke, D. N., Sethuraman, A., Hoogewijs, D., Schörg, A., Gotwald, L., Fan, M., Wenger, R. H., et al. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0510-x · Cited by 196
The genomic landscape of schwannoma
Agnihotri, S., Jalali, S., Wilson, M. R., Danesh, A., Li, M., Klironomos, G., Krieger, J. R., Mansouri, A., Khan, O. H., Mamatjan, Y., et al. (2016) · Nature Genetics · doi:10.1038/ng.3688 · Cited by 196
The cGAS/STING Pathway: A Novel Target for Cancer Therapy
Gan, Y., Li, X., Han, S., Liang, Q., Ma, X., Rong, P., Wang, W., & Li, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.795401 · Cited by 194
PI3K mutations in breast cancer: prognostic and therapeutic implications
Mukohara, T. (2015) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s60696 · Cited by 189
Yardley, D. A., Weaver, R., Melisko, M., Saleh, M. N., Arena, F. P., Forero, A., Cigler, T., Stopeck, A., Citrin, D. L., Oliff, I. A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2959 · Cited by 189
Chen, J. C., Alvarez, M. J., Talos, F., Dhruv, H., Rieckhof, G. E., Iyer, A., Diefes, K. L., Aldape, K., Berens, M., Shen, M. M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.021 · Cited by 188
The NF1 gene revisited - from bench to bedside
Yap, Y. S., McPherson, J. R., Ong, C. K., Rozen, S., Teh, B. T., Lee, A. S. G., & Callen, D. F. (2014) · Oncotarget · doi:10.18632/oncotarget.2194 · Cited by 189
Molecular Markers for Breast Cancer: Prediction on Tumor Behavior
Hirata, B. K. B., Oda, J. M. M., Guembarovski, R. L., Ariza, C. B., de Oliveira, C. E. C., & Watanabe, M. A. E. (2014) · Disease Markers · doi:10.1155/2014/513158 · Cited by 192
Stirzaker, C., Zotenko, E., Song, J. Z., Qu, W., Nair, S. S., Locke, W. J., Stone, A. M., Armstong, N. J., Robinson, M. D., Dobrovic, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms6899 · Cited by 193
McCartney, A., Migliaccio, I., Bonechi, M., Biagioni, C., Romagnoli, D., Luca, F. D., Galardi, F., Risi, E., Santo, I. D., Benelli, M., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00666 · Cited by 195
The Role of Immune Cells in Breast Tissue and Immunotherapy for the Treatment of Breast Cancer
Goff, S. L., & Danforth, D. N. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.06.011 · Cited by 188
Rodon, J. A., Braña, I., Siu, L. L., Jonge, M. J. D., Homji, N. F., Mills, D., di Tomaso, E., Sarr, C., Trandafir, L., Massacesi, C., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0082-9 · Cited by 190
Isobe, T., Hisamori, S., Hogan, D. J., Zabala, M., Hendrickson, D. G., Dalerba, P. D., Cai, S., Scheeren, F. A., Kuo, A. H., Sikandar, S. S., et al. (2014) · eLife · doi:10.7554/elife.01977 · Cited by 188
Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed
den Brok, W. D., Speers, C. H., Gondara, L., Baxter, E., Tyldesley, S. K., & Lohrisch, C. A. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-4080-9 · Cited by 189
Targeting the cell cycle in breast cancer: towards the next phase
Thu, K. L., Soria‐Bretones, I., Mak, T. W., & Cescon, D. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1502567 · Cited by 192
Recent Advances in Oligonucleotide Therapeutics in Oncology
Xiong, H., Veedu, R. N., & Diermeier, S. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073295 · Cited by 194
Strong, M. J., Xu, G., Morici, L., Splinter Bon-Durant, S., Baddoo, M., Lin, Z., Fewell, C., Taylor, C. M., & Flemington, E. K. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004437 · Cited by 186
Yamamoto, M., Taguchi, Y., Ito-Kureha, T., Semba, K., Yamaguchi, N., & Inoue, J. (2013) · Nature Communications · doi:10.1038/ncomms3299 · Cited by 188
Mérino, D., Whittle, J. R., Vaillant, F., Serrano, A., Gong, J.-N., Giner, G., Maragno, A. L., Chanrion, M., Schneider, E., Pal, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aam7049 · Cited by 195
Modeling Breast Cancer Using CRISPR-Cas9–Mediated Engineering of Human Breast Organoids
Dekkers, J. F., Whittle, J. R., Vaillant, F., Chen, H., Dawson, C. A., Liu, K., Geurts, M. H., Herold, M. J., Clevers, H. C., Lindeman, G. J., et al. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz196 · Cited by 194
Huang, Y., Zhang, H., Li, Z., Du, T., Chen, Y., Wang, Y., Ni, H.-H., Zhang, K., Mai, J., Hu, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22618-x · Cited by 188
Middlebrooks, C. D., Banday, A. R., Matsuda, K., Udquim, K.-I., Onabajo, O. O., Paquin, A., Figueroa, J. D., Zhu, B., Koutros, S., Kubo, M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3670 · Cited by 185
Phospholipids as cancer biomarkers: Mass spectrometry‐based analysis
Bandu, R., Mok, H. J., & Kim, K. P. (2016) · Mass Spectrometry Reviews · doi:10.1002/mas.21510 · Cited by 189
Local microRNA delivery targets Palladin and prevents metastatic breast cancer
Gilam, A., Conde, J., Weissglas‐Volkov, D., Oliva, N., Friedman, E., Artzi, N., & Shomron, N. (2016) · Nature Communications · doi:10.1038/ncomms12868 · Cited by 185
Liubomirski, Y., Lerrer, S., Meshel, T., Rubinstein-Achiasaf, L., Morein, D., Wiemann, S., Körner, C., & Ben‐Baruch, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00757 · Cited by 188
Castagnoli, L., Cancila, V., Cordoba-Romero, S. L., Faraci, S., Talarico, G., Belmonte, B., Iorio, M. V., Milani, M., Volpari, T., Chiodoni, C., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0700-2 · Cited by 184
Kennedy, J. J., Abbatiello, S. E., Kim, K., Yan, P., Whiteaker, J. R., Lin, C., Kim, J. S., Zhang, Y., Wang, X., Ivey, R. G., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2763 · Cited by 184
Gilkes, D. M., Xiang, L., Lee, S. J., Chaturvedi, P., Hubbi, M. E., Wirtz, D., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321510111 · Cited by 184
RetractedExpanding the computational toolbox for mining cancer genomes
Ding, L., Wendl, M. C., McMichael, J. F., & Raphael, B. J. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3767 · Cited by 188
Maycotte, P., Gearheart, C. M., Barnard, R., Aryal, S., Levy, J. M. M., Fosmire, S. P., Hansen, R. J., Morgan, M. J., Porter, C. C., Gustafson, D. L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3470 · Cited by 188
Digital image analysis outperforms manual biomarker assessment in breast cancer
Stålhammar, G., Martínez, N. F., Lippert, M. F., Tobin, N. P., Mølholm, I., Kis, L. L., Rosin, G., Rantalainen, M., Pedersen, L., Bergh, J. C. S., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.34 · Cited by 185
Breast cancer histopathology image classification through assembling multiple compact CNNs
Zhu, C., Song, F., Wang, Y., Dong, H., Guo, Y., & Liu, J. (2019) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-019-0913-x · Cited by 184
Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer
Gaynor, N., Crown, J. P., & Collins, D. M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.016 · Cited by 185
A comprehensive analysis of breast cancer microbiota and host gene expression
Thompson, K. J., Ingle, J. N., Tang, X., Chia, N., Jeraldo, P. R., Walther-Antonio, M. R., Kandimalla, K. K., Johnson, S., Yao, J. Z., Harrington, S. C., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0188873 · Cited by 183
Methylation of cell-free circulating DNA in the diagnosis of cancer
Warton, K., & Samimi, G. (2015) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2015.00013 · Cited by 188
In vivomodels in breast cancer research: progress, challenges and future directions
Holen, I., Speirs, V., Morrissey, B., & Blyth, K. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.028274 · Cited by 183
Zheng, S., Webster, A. P., Dong, D., Feber, A., Graham, D. G., Sullivan, R., Jevons, S., Lovat, L. B., Beck, S., Widschwendter, M., et al. (2018) · Epigenomics · doi:10.2217/epi-2018-0037 · Cited by 184
Schettini, F., Pascual, T., Conte, B., Chic, N., Brasó‐Maristany, F., Galván, P., Martínez‐Sáez, O., Adamo, B., Vidal, M. J., Muñoz-Mateu, M., et al. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101965 · Cited by 192
Barroso‐Sousa, R., Keenan, T. E., Pernas, S., Exman, P., Jain, E., Garrido-Castro, A. C., Hughes, M. E., Bychkovsky, B., Umeton, R., Files, J. L., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3507 · Cited by 187
Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation
Farabaugh, S. M., Boone, D. N., & Lee, A. V. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00059 · Cited by 190
Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies
Du, W., & Elemento, O. (2014) · Oncogene · doi:10.1038/onc.2014.291 · Cited by 185
Absolute Assignment of Breast Cancer Intrinsic Molecular Subtype
Paquet, É. R., & Hallett, M. T. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju357 · Cited by 186
Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes
Győrffy, B., Bottai, G., Fleischer, T., Munkácsy, G., Budczies, J., Paladini, L., Børresen‐Dale, A., Kristensen, V. N., & Santarpia, L. (2015) · International Journal of Cancer · doi:10.1002/ijc.29684 · Cited by 182
Metadata
- Authors
- The Cancer Genome Atlas Network
- Corresponding author
- The Cancer Genome Atlas Network
- Venue
- Nature
- Published
- 2012-09-23
- Volume
- 490
- Issue
- 7418
- Pages
- 61-70
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3465532
- OpenAlex
- W4301159569
- Cited by
- 12,129
- References
- 56
- Citations by year
- 2026: 552 · 2025: 690 · 2024: 761 · 2023: 781 · 2022: 918 · 2021: 1164 · 2020: 1005 · 2019: 961 · 2018: 942 · 2017: 949 · 2016: 979 · 2015: 909 · 2014: 879 · 2013: 590 · 2012: 40
- FWCI
- 256.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- U.S. Department of Defense
- Breast Cancer Research Foundation (P50CA116201)
- Henry M. Jackson Foundation
- National Institutes of Health
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG004028)
- National Cancer Institute (R01CA094143, U24CA143882, U01CA084955, U24CA143840, U24CA143858, U24CA144025, K08CA148912, U24CA143866, U24CA143883, U24CA143845, U24CA143867, U24CA143848, U24CA143799, U24CA143835, P50 CA 58223, P30CA016672, P30CA016058, P50CA058223, P50CA116201, P30CA016086)
- U.S. National Library of Medicine (R01LM009722)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Keywords
- breast cancer, molecular subtypes, tumor heterogeneity, somatic mutations, TP53, PIK3CA, GATA3, MAP3K1, luminal A, HER2-enriched breast cancer, basal-like breast cancer, high-grade serous ovarian cancer, DNA methylation, copy number variation, gene expression signatures, signaling pathways, tumor microenvironment, multi-omics integration
- MeSH terms
- Breast Neoplasms, DNA Mutational Analysis, Female, Humans, Mutation, Ovarian Neoplasms, Receptors, Estrogen, RNA, Messenger, RNA, Neoplasm, Genome, Human, Gene Expression Regulation, Neoplastic, Genes, p53, Retinoblastoma Protein, Genes, erbB-2, Genetic Heterogeneity, DNA Methylation, Genes, BRCA1, Phosphatidylinositol 3-Kinases, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Genomics, MicroRNAs, Protein Array Analysis, Proteomics, MAP Kinase Kinase Kinase 1, GATA3 Transcription Factor, Genes, Neoplasm, DNA Copy Number Variations, Class I Phosphatidylinositol 3-Kinases, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
